P

PDC*line Pharma

32 employees

PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Plasmacytoid Dendritic Cells
Health Care
Clinical development
Therapeutics
Therapeutic vaccines
neoantigens
Cancer immunotherapy

Date founded

2014

Funding rounds raised

Total raised

$15M

from 13 investors over 13 rounds

P

PDC*line Pharma raised $13M on December 6, 2021

Investors: -, Korea Investment Partners, SRIW, Brain Asset Management, ALPHACHIPS Corp, UTC Investment Co.,Ltd., SFPI-FPIM and -

P

PDC*line Pharma raised $15M on January 22, 2020

Investors: Korea Investment Partners, -, SRIW and UTC Investment Co.,Ltd.

P

PDC*line Pharma raised $4.3M on December 6, 2016

Investors: SFPI-FPIM

FAQ